Moreover, IL-33 can act as a novel immunoadjuvant to augment vaccine-induced protective antiviral CD8+ T cell responses and thus to improve T cell responses induced by an anti-tumor DNA vaccine [29, 31]. Here, IL33 is linked to neoplasm.